0.08Open0.08Pre Close0 Volume6 Open Interest10.00Strike Price0.00Turnover223.59%IV144.66%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.0928Delta0.0730Gamma51.50Leverage Ratio-0.0084Theta0.0002Rho4.78Eff Leverage0.0017Vega
Perspective Therapeutics Stock Discussion
I don't even trust my mind
losing everybody
they can never take my grind
📊⚡️📊
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and eff...
Larger Image: tradingview.com...
$Perspective Therapeutics (CATX.US)$
No comment yet